|
Variable
|
CinnoRA®
|
Humira®
|
P value
|
|---|
|
Age
|
48.29 ± 12.72
|
47.59 ± 11.48
|
0.73
|
|
Sex, n (%)
|
|
Male
|
10 (14.71%)
|
8 (11.76%)
|
0.85*
|
|
Female
|
58 (85.29%)
|
60 (88.24%)
|
|
Swollen joint count, 28 joints
|
9.96 ± 7.39
|
9.46 ± 6.98
|
0.69
|
|
Tender joint count, 28 joints
|
9.46 ± 8.23
|
9.66 ± 7.97
|
0.88
|
|
Patient assessment of pain
|
67.21 ± 23.51
|
70.22 ± 21.93
|
0.44
|
|
Patient global assessment of disease activity
|
70.15 ± 20.35
|
70.74 ± 22.21
|
0.87
|
|
Physician’s global assessment of disease activity
|
68.97 ± 17.38
|
70.44 ± 17.68
|
0.63
|
|
CRP (mg/L)
|
21.40 ± 25.98
|
18.90 ± 23.90
|
0.57
|
|
ESR (mm/h)
|
32.65 ± 21.24
|
31.12 ± 24.01
|
0.69
|
|
HAQ
|
1.25 (1.38)
|
1.38 (1.13)
|
0.56†
|
|
DAS28-ESR
|
5.51 ± 1.24
|
5.47 ± 1.28
|
0.87
|
|
RF
|
63.76 ± 57.22
|
76.95 ± 65.66
|
0.22
|
- Data are shown as mean ± SD and were analyzed using the independent t test unless stated otherwise. CRP C-reactive protein, DAS28 disease activity score in 28 joints, ESR erythrocyte sedimentation rate, HAQ health assessment questionnaire, RF rheumatoid factor. *Data were analyzed using Pearson's chi-squared test. †Scores are shown as median (interquartile range) and were analyzed using the Mann-Whitney U test
